Drug Trial News

RSS

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

Study investigates gene expression signature to predict response to bevacizumab

A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin-), according to new research from The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.

3 Jun 2013

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

3 Jun 2013

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology.

3 Jun 2013

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.

1 Jun 2013

Researchers discover potential biomarkers to identify patients with head and neck cancer

Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.

1 Jun 2013

MannKind completes AFREZZA Phase 3 clinical study in patients with type 1 diabetes

MannKind Corporation today announced that all follow-up visits have been completed for the patients enrolled in Study 171, a Phase 3 clinical study of AFREZZA (insulin human [rDNA origin]) inhalation powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation inhaler. MannKind expects to release data from this study later this summer.

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

Omeros announces positive results from OMS824 Phase 1 clinical program

Omeros Corporation today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program.

31 May 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

PharmAthene announces lifting of clinical hold on proposed SparVax Phase II study

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration has lifted the clinical hold previously placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine.

31 May 2013

New hope for children with multi-system LCH

A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis can achieve survival rates as high as 84 percent-a full 15 percent improvement over the previous clinical trial in this series.

30 May 2013

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of a Phase 2b clinical study of TC-5214 as a treatment for overactive bladder.

29 May 2013

Pacira Pharmaceuticals reports results of EXPAREL Phase 2/3 clinical trial for TKA

Pacira Pharmaceuticals, Inc. today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery.

29 May 2013

Standalone labelling service announced by Packaging Coordinators Inc (PCI)

Packaging Coordinators Inc (PCI), formerly AndersonBrecon, a global supplier of pharmaceutical commercial packaging solutions and clinical trials services, today announced a standalone labelling service that can dramatically reduce design and printing turnaround times. The fast response labelling solution has been developed to meet the ever-evolving needs of customers in the industry, providing bespoke, around-the-clock support and ensuring that even projects where labelling requirements change unexpectedly are successfully kept on track.

From Packaging Coordinators Inc. (PCI) 29 May 2013

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Alkermes plc today presented positive results from a phase 1 study of ALKS 3831, a novel drug candidate for the treatment of schizophrenia, in an oral session at the 53rd Annual New Clinical Drug Evaluation Unit Meeting in Hollywood, Fla.

28 May 2013

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.

28 May 2013

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

Cancer vaccine company DCPrime today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia.

28 May 2013

Blinding and blinding assessment rarely documented in trial reports

A paper published in the current issue of P&P? tests the widely accepted assumption in drug trials: neither evaluators nor patients know whether the patient is getting drug or placebo (double blindness).

28 May 2013

Drug Trial News

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

Study investigates gene expression signature to predict response to bevacizumab

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Researchers discover potential biomarkers to identify patients with head and neck cancer

MannKind completes AFREZZA Phase 3 clinical study in patients with type 1 diabetes

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Omeros announces positive results from OMS824 Phase 1 clinical program

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

PharmAthene announces lifting of clinical hold on proposed SparVax Phase II study

New hope for children with multi-system LCH

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Pacira Pharmaceuticals reports results of EXPAREL Phase 2/3 clinical trial for TKA

Standalone labelling service announced by Packaging Coordinators Inc (PCI)

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

Blinding and blinding assessment rarely documented in trial reports

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News